HERANTIS PHARMA OYJ |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.42 EUR | -2.74% |
|
-2.07% | -9.84% |
| Mar. 06 | Herantis Pharma Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 06 | Transcript : Herantis Pharma Oyj, 2023 Earnings Call, Mar 06, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 51.77 | 40.49 | 26.65 | 27.91 | 31.75 | 28.63 | - |
| Enterprise Value (EV) 1 | 51.99 | 34.37 | 26.65 | 27.91 | 31.75 | 24.43 | 28.63 |
| P/E ratio | -5.66 x | -3.35 x | -1.92 x | - | - | - | - |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | 22 x | - |
| EV / Revenue | - | - | - | - | - | 18.8 x | - |
| EV / EBITDA | -8.51 x | -4.81 x | - | -3.56 x | 206 x | -8.14 x | - |
| EV / FCF | -8,725,099 x | -4,015,166 x | - | -3,048,427 x | - | - | - |
| FCF Yield | -0% | -0% | - | -0% | - | - | - |
| Price to Book | 28 x | 5.33 x | - | - | - | - | - |
| Nbr of stocks (in thousands) | 6,680 | 9,757 | 11,104 | 16,912 | 20,161 | 20,161 | - |
| Reference price 2 | 7.750 | 4.150 | 2.400 | 1.650 | 1.575 | 1.420 | 1.420 |
| Announcement Date | 2/27/20 | 3/3/21 | 3/3/22 | 3/28/23 | 3/6/24 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 1.3 | - |
| EBITDA 1 | -6.109 | -7.143 | - | -7.833 | 0.154 | -3 | - |
| EBIT 1 | -7.155 | -8.071 | - | -7.993 | 0.154 | -3 | -4 |
| Operating Margin | - | - | - | - | - | -230.77% | - |
| Earnings before Tax (EBT) 1 | -8.005 | -9.153 | - | -9.324 | 0.28 | -3.2 | -4 |
| Net income 1 | -8.005 | -9.153 | -12.77 | -9.324 | 0.28 | -3.2 | -4 |
| Net margin | - | - | - | - | - | -246.15% | - |
| EPS | -1.370 | -1.240 | -1.250 | - | - | - | - |
| Free Cash Flow | -5.958 | -8.561 | - | -9.154 | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 2/27/20 | 3/3/21 | 3/3/22 | 3/28/23 | 3/6/24 | - | - |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | 0.21 | - | - | - | - | - | - |
| Net Cash position 1 | - | 6.12 | - | - | - | 4.2 | - |
| Leverage (Debt/EBITDA) | -0.035 x | - | - | - | - | - | - |
| Free Cash Flow | -5.96 | -8.56 | - | -9.15 | - | - | - |
| ROE (net income / shareholders' equity) | -909% | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | 0.2800 | 0.7800 | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 2/27/20 | 3/3/21 | 3/3/22 | 3/28/23 | 3/6/24 | - | - |
1EUR in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -9.84% | 30.67M | |
| -2.63% | 102B | |
| +1.62% | 96.29B | |
| +1.72% | 22.18B | |
| -16.67% | 21.2B | |
| -8.28% | 18.31B | |
| -38.74% | 17.38B | |
| -13.21% | 16.36B | |
| +5.41% | 13.97B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- HRTIS Stock
- Financials Herantis Pharma Oyj
